Robert Anthony Doti
Eli Lilly and Company
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Robert Anthony Doti.
Bioorganic & Medicinal Chemistry Letters | 2015
Timothy Paul Burkholder; Brian Eugene Cunningham; Joshua Ryan Clayton; Peter Ambrose Lander; Matthew L. Brown; Robert Anthony Doti; Gregory L. Durst; Chahrzad Montrose-Rafizadeh; Constance King; Harold E. Osborne; Robert M. Amos; Richard W. Zink; Lawrence E. Stramm; Thomas P. Burris; Guemalli R. Cardona; Debra L. Konkol; Charles Reidy; Michael E. Christe; Michael James Genin
The design, synthesis, and structure activity relationships for a novel series of indoles as potent, selective, thyroid hormone receptor β (TRβ) agonists is described. Compounds with >50× binding selectivity for TRβ over TRα were generated and evaluation of compound 1c from this series in a model of dyslipidemia demonstrated positive effects on plasma lipid endpoints in vivo.
Bioorganic & Medicinal Chemistry Letters | 2016
Norman E. Hughes; Thomas John Bleisch; Scott Alan Jones; Timothy I. Richardson; Robert Anthony Doti; Yong Wang; Stephanie L. Stout; Gregory L. Durst; Mark Chambers; J.L. Oskins; C. Lin; Lisa A. Adams; Todd J. Page; Robert J. Barr; Richard W. Zink; Harold E. Osborne; Chahrzad Montrose-Rafizadeh; Bryan H. Norman
A series of triaryl pyrazoles were identified as potent pan antagonists for the retinoic acid receptors (RARs) α, β and γ. X-ray crystallography and structure-based drug design were used to improve selectivity for RARγ by targeting residue differences in the ligand binding pockets of these receptors. This resulted in the discovery of novel antagonists which maintained RARγ potency but were greater than 500-fold selective versus RARα and RARβ. The potent and selective RARγ antagonist LY2955303 demonstrated good pharmacokinetic properties and was efficacious in the MIA model of osteoarthritis-like joint pain. This compound demonstrated an improved margin to RARα-mediated adverse effects.
Archive | 2008
Michael Gregory Bell; Robert Anthony Doti; Matthew Scott Dowling; Michael James Genin; Peter Ambrose Lander; Tianwei Ma; Nathan Bryan Mantlo; Jason Matthew Ochoada; Lindsay Scott Stelzer; Ryan Edward Stites; Alan M. Warshawsky
Bioorganic & Medicinal Chemistry Letters | 2005
David Andrew Neel; Matthew L. Brown; Peter Ambrose Lander; Timothy Alan Grese; Jean Marie Defauw; Robert Anthony Doti; Todd Fields; Sally Ann Kelley; Stephon C. Smith; Karen M. Zimmerman; Mitchell I. Steinberg; Prabhakar Kondaji Jadhav
Archive | 2007
Michael Gregory Bell; Michael James Genin; Peter Ambrose Lander; Tianwei Ma; Lindsay Scott Stelzer; Robert Anthony Doti; Ryan Edward Stites; Francisco Javier Agejas-Chicharro; Melendo Ana Belen Bueno; Peter Rudolph Manninen; Jason Matthew Ochoada; Quanrong Shen; Alan M. Warshawsky
Archive | 2014
Thomas John Bleisch; Robert Anthony Doti; Lance Allen Pfeifer; Bryan H. Norman
Archive | 2008
Michael Gregory Bell; Robert Anthony Doti; Matthew Scott Dowling; Michael J. Genin; Peter Ambrose Lander; Tianwei Ma; Natha
Archive | 2007
Michael Gregory Bell; Robert Anthony Doti; Matthew Scott Dowling; Michael J. Genin; Peter Ambrose Lander; Tianwei Ma; Nathan Bryan Mantlo; Jason Matthew Ochoada; Lindsay Scott Stelzer; Ryan Edward Stites; Alan M. Warshawsky
Archive | 2007
Michael Gregory Bell; Robert Anthony Doti; Matthew Scott Dowling; Michael J. Genin; Peter Ambrose Lander; Tianwei Ma; Nathan Bryan Mantlo; Jason Matthew Ochoada; Lindsay Scott Stelzer; Ryan Edward Stites; Alan M. Warshawsky
Archive | 2007
Michael Gregory Bell; Robert Anthony Doti; Michael J. Genin; Peter Ambrose Lander; Tianwei Ma; Peter R. Manninen; Jason Matthew Ochoada; Fucheng Qu; Lindsay Scott Stelzer; Ryan Edward Stites; Alan M. Warshawsky